Management of Hepatitis B Patients Receiving Anti-TB Medications

Pre-Treatment Assessment and Risk Stratification

The American Thoracic Society recommends obtaining baseline hepatic measurements including AST, ALT, alkaline phosphatase, and bilirubin to establish the degree of liver dysfunction in hepatitis B patients with elevated transaminases 3
The American Journal of Respiratory and Critical Care Medicine suggests performing hepatitis B serologic testing (HBsAg, anti-HBc) and hepatitis C screening if not already done, as coinfection significantly increases hepatotoxicity risk 4
The American College of Gastroenterology recommends arranging hepatology consultation for HBsAg-positive patients before starting treatment due to HBV reactivation risk 2
The Centers for Disease Control and Prevention advise ruling out active TB disease through history, physical examination, chest radiography, and bacteriologic studies to confirm treatment indication 2

The American Thoracic Society recommends starting standard first-line anti-TB therapy (isoniazid, rifampin, pyrazinamide, ethambutol) immediately in patients with ALT/AST 2-3 times the upper limit of normal without symptoms 1
The European Respiratory Society suggests checking liver function tests weekly for 2 weeks, then biweekly for the first 2 months of treatment in hepatitis B patients 1
The Infectious Diseases Society of America recommends performing monthly clinical evaluations checking for hepatitis symptoms including fever, malaise, vomiting, jaundice, or abdominal pain 1

The American Journal of Respiratory and Critical Care Medicine advises stopping all hepatotoxic TB drugs (isoniazid, rifampin, pyrazinamide) immediately if AST/ALT rises to 5 times the upper limit of normal without symptoms 5
The European Respiratory Society recommends stopping all hepatotoxic TB drugs immediately if AST/ALT rises to 3 times the upper limit of normal with hepatitis symptoms (fever, malaise, vomiting) 5
The American College of Gastroenterology suggests stopping all hepatotoxic TB drugs immediately if bilirubin rises above normal range (jaundice develops) 6

The American Thoracic Society recommends immediately initiating non-hepatotoxic therapy with streptomycin and ethambutol until liver function normalizes 6
The Infectious Diseases Society of America suggests that this combination provides adequate TB coverage while avoiding hepatotoxic agents 6

The European Respiratory Society recommends reintroducing isoniazid first at 50 mg/day, increasing to 300 mg/day after 2-3 days if no reaction 1
The American Thoracic Society suggests adding rifampin at 75 mg/day, increasing to 300 mg after 2-3 days, then to full dose (450-600 mg based on weight) after another 2-3 days 1
The Infectious Diseases Society of America recommends checking liver function tests daily during each reintroduction phase 1

The American College of Gastroenterology advises never delaying TB treatment solely due to hepatitis B status in non-cirrhotic patients - untreated TB carries higher mortality risk than hepatotoxicity with appropriate monitoring 2
The European Respiratory Society recommends never using rifampin-pyrazinamide combination for latent TB in patients with any form of liver disease - this combination has unacceptably high rates of severe hepatotoxicity and death 3

The American Thoracic Society suggests using isoniazid and rifampin for 9 months total, supplemented with ethambutol for the initial 2 months if pyrazinamide is the offending drug 1
The Infectious Diseases Society of America recommends consulting a TB specialist for alternative regimens using second-line agents including fluoroquinolones, which are safe in hepatotoxicity 6